| Index | — | P/E | 8.70 | EPS (ttm) | 2.84 | Insider Own | — | Shs Outstand | 1.22B | Perf Week | 4.22% |
| Market Cap | 30.23B | Forward P/E | 8.80 | EPS next Y | 2.81 | Insider Trans | — | Shs Float | 1.22B | Perf Month | -0.04% |
| Enterprise Value | 29.77B | PEG | 0.61 | EPS next Q | 1.33 | Short Float | 0.06% | Perf Quarter | -17.80% | ||
| Income | 3.63B | P/S | 1.00 | EPS this Y | 12.97% | Short Ratio | 0.66 | Perf Half Y | -18.13% | ||
| Sales | 30.20B | P/B | 1.47 | EPS next Y | 21.29% | ROA | 1.62% | Short Interest | 740.99K | Perf YTD | -20.63% |
| Book/sh | 16.85 | P/C | 5.13 | EPS next 5Y | 14.21% | ROE | 18.25% | 52W High | 34.03 -26.30% | Perf Year | -11.18% |
| Cash/sh | 4.81 | P/FCF | 21.13 | EPS past 3/5Y | — -1.26% | ROIC | 1.67% | 52W Low | 23.31 7.59% | Perf 3Y | 22.89% |
| Dividend Est. | 0.36 (1.42%) | EV/EBITDA | 6.48 | Sales past 3/5Y | 46.99% -5.18% | Gross Margin | 71.22% | Volatility | 1.01% 1.15% | Perf 5Y | -39.59% |
| Dividend TTM | 0.56 (2.21%) | EV/Sales | 0.99 | EPS Y/Y TTM | 9.23% | Oper. Margin | 15.32% | ATR (14) | 0.40 | Perf 10Y | -26.11% |
| Dividend Ex-Date | Sep 11, 2026 | Quick Ratio | — | Sales Y/Y TTM | 83.71% | Profit Margin | 12.15% | RSI (14) | 52.08 | Recom | 2.63 |
| Dividend Gr. 3/5Y | 10.89% -4.59% | Current Ratio | — | EPS Q/Q | -23.33% | SMA20 | 2.66% | Beta | 0.70 | Target Price | 39.30 |
| Payout | 15.07% | Debt/Eq | 0.26 | Sales Q/Q | 19.35% | SMA50 | -3.52% | Rel Volume | 1.28 | Prev Close | 24.70 |
| Employees | 15,338 | LT Debt/Eq | 0.23 | Earnings | Mar 24 | SMA200 | -13.46% | Avg Volume | 1.20M | Price | 25.08 |
| IPO Date | Jun 29, 2000 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -40.98% 0.00% | Net Debt/EBITDA | -0.10 | Volume | 1,538,575 | Change | 1.54% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-03-26 | Initiated | Berenberg | Buy | $39 |
| Mar-23-21 | Upgrade | HSBC | Hold → Buy | |
| Mar-17-17 | Upgrade | JP Morgan | Underweight → Neutral | |
| Oct-13-16 | Downgrade | Societe Generale | Hold → Sell | |
| Jul-05-16 | Downgrade | JP Morgan | Neutral → Underweight | |
| May-31-16 | Downgrade | Societe Generale | Buy → Hold | |
| Jul-20-15 | Downgrade | Jefferies | Buy → Hold |
Prudential plc, operating through its various subsidiaries, delivers a diverse array of financial solutions to individuals across Asia and Africa, encompassing life and health coverage, retirement planning, and comprehensive asset management services. Its product portfolio includes extensive health and protection plans, along with various savings instruments such as participating, unit-linked, and conventional policies. The company additionally offers insurance against widespread critical illnesses like cancer, strokes, and heart attacks, and provides specialized protection for tropical diseases such as dengue, malaria, and measles. Furthermore, Prudential plc manages a broad spectrum of investment portfolios for both institutional clients and private individuals, utilizing strategies that span equities, fixed income, multi-asset approaches, quantitative methods, and alternative investments. These products and services are made available through its dedicated agency network, banking collaborators, and independent brokers. Founded in 1848, the firm's primary operations are based in London, United Kingdom.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 30,203 | 27,781 | 8,139 | 11,970 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,385 | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 25,818 | 27,781 | 8,139 | 11,970 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 21,415 | 22,835 | 5,186 | 9,873 | — | — | — | — | — | |
| Operating Income | 4,403 | 4,946 | 2,953 | 2,097 | — | — | — | — | — | |
| Interest Expense | 192 | 183 | 171 | 172 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 192 | 183 | 171 | 172 | — | — | — | — | — | |
| Net Income Before Taxes | 4,403 | 4,946 | 2,953 | 2,097 | — | — | — | — | — | |
| Income Taxes | 663 | 823 | 538 | 385 | — | — | — | — | — | |
| Consolidated Net Income | 3,634 | 3,982 | 2,285 | 1,701 | — | — | — | — | — | |
| Net Income From Continuing Operations | 3,741 | 4,123 | 2,415 | 1,712 | — | — | — | — | — | |
| Net Income | 3,634 | 3,982 | 2,285 | 1,701 | — | — | — | — | — | |
| EPS (Recurring) | 2.86 | 3.10 | 1.68 | 2.48 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.86 | 3.10 | 1.68 | 2.48 | — | — | — | — | — | |
| EPS (Diluted) | 2.84 | 3.06 | 1.68 | 2.48 | — | — | — | — | — | |
| EBITDA | 4,595 | 5,129 | 3,124 | 3,056 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 8.83 | 10.17 | 9.49 | 9.05 | — | — | — | — | — | |
| Price To Sales Ratio | 1.04 | 1.45 | 2.66 | 1.28 | — | — | — | — | — | |
| Gross Margin | 85.48 | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | 14.58 | 17.80 | 36.28 | 17.52 | — | — | — | — | — | |
| Net Margin | 12.03 | 14.33 | 28.07 | 14.21 | — | — | — | — | — | |
| Shares Outstanding | 1,258 | 1,290 | 1,358 | 685 | — | — | — | — | — | |
| Market Capitalization | 31,551 | 40,145 | 21,647 | 15,378 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |